Delcath Systems (NASDAQ:DCTH), an interventional oncology company specializing in treatments for primary and metastatic liver cancers, announced preliminary unaudited financial results and business updates for the fourth quarter and full year ended December 31, 2025.
Total revenue for the fourth quarter is expected to be approximately $20.7 million, contributing to full-year revenue of approximately $85.2 million.
The company's flagship HEPZATO KIT, which delivers melphalan hydrochloride for injection directly to the liver via the HEPZATO Hepatic Delivery System, generated an estimated $19 million in fourth-quarter revenue and $78.8 million for the full year.
CHEMOSAT, the European version of the hepatic delivery system, contributed approximately $1.7 million in the fourth quarter and $6.4 million for the year.
Delcath also continued executing its capital return strategy, repurchasing 628,572 common shares for $6 million through December 31, 2025, under its $25 million approved share buyback program.
Elsewhere, the company strengthened its balance sheet, ending the year with approximately $91 million in cash and short-term investments and no debt, an increase from $88.9 million as of September 30, 2025.
Delcath expects to release final financial results for the fourth quarter and full year 2025, along with a detailed business update, during its upcoming annual financial results conference call.